Washington : There could soon be a treatment for intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, as researchers have have now found how two genetic mutations in liver cells may drive tumour formation in iCCA, says IANS.
Two mutant proteins IDH1 and IDH2 are linked to cancer, the findings showed. “iCCA is resistant to standard treatments like chemotherapy and radiation,” said contributing author Josep Maria Llovet from Icahn School of Medicine at Mount Sinai in the US.
“Our findings provide novel insights into the development of iCCA and offers a possible treatment option for patients suffering from this fatal disease,” Llovet added.
Past studies have found IDH mutations to be among the most common genetic differences seen in patients with iCCA, but how they contribute to cancer development was unknown going into the current effort.
iCCA strikes bile ducts, tube-like structures in the liver that carry bile, which is required for the digestion of food.